AR045738A1 - Derivados de bencimidazol n3 alquilados como inhibidores de mek - Google Patents

Derivados de bencimidazol n3 alquilados como inhibidores de mek

Info

Publication number
AR045738A1
AR045738A1 ARP040103103A ARP040103103A AR045738A1 AR 045738 A1 AR045738 A1 AR 045738A1 AR P040103103 A ARP040103103 A AR P040103103A AR P040103103 A ARP040103103 A AR P040103103A AR 045738 A1 AR045738 A1 AR 045738A1
Authority
AR
Argentina
Prior art keywords
aryl
heteroaryl
heterocyclyl
nr3r4
alkyl
Prior art date
Application number
ARP040103103A
Other languages
English (en)
Spanish (es)
Inventor
Eli M Wallace
Joseph Lyssikatos
Allison L Marlow
T Brian Hurley
Kevin Koch
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AR045738A1 publication Critical patent/AR045738A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP040103103A 2003-08-29 2004-08-27 Derivados de bencimidazol n3 alquilados como inhibidores de mek AR045738A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/652,733 US7235537B2 (en) 2002-03-13 2003-08-29 N3 alkylated benzimidazole derivatives as MEK inhibitors

Publications (1)

Publication Number Publication Date
AR045738A1 true AR045738A1 (es) 2005-11-09

Family

ID=34273411

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103103A AR045738A1 (es) 2003-08-29 2004-08-27 Derivados de bencimidazol n3 alquilados como inhibidores de mek

Country Status (18)

Country Link
US (2) US7235537B2 (OSRAM)
EP (1) EP1663210B1 (OSRAM)
JP (1) JP5026076B2 (OSRAM)
KR (1) KR20060121853A (OSRAM)
CN (1) CN1874768A (OSRAM)
AR (1) AR045738A1 (OSRAM)
AU (1) AU2004270166A1 (OSRAM)
BR (1) BRPI0413152A (OSRAM)
CA (1) CA2537098A1 (OSRAM)
ES (1) ES2628959T3 (OSRAM)
IL (1) IL173935A (OSRAM)
IS (1) IS8384A (OSRAM)
MX (1) MXPA06002268A (OSRAM)
NO (1) NO20061432L (OSRAM)
RU (1) RU2006109600A (OSRAM)
TW (1) TW200524879A (OSRAM)
WO (1) WO2005023251A1 (OSRAM)
ZA (1) ZA200602588B (OSRAM)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478374C (en) * 2002-03-13 2009-01-06 Eli M. Wallace N3 alkylated benzimidazole derivatives as mek inhibitors
WO2005009975A2 (en) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP4869075B2 (ja) * 2003-11-19 2012-02-01 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの複素環阻害剤及びその使用方法
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
BRPI0416852A (pt) * 2003-11-21 2007-02-27 Array Biopharma Inc inibidores da quinase akt
RU2500673C2 (ru) * 2005-05-18 2013-12-10 Астразенека Аб Гетероциклические ингибиторы мек и способы их применения
EP1934174B1 (en) * 2005-10-07 2011-04-06 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
PL2090575T3 (pl) 2005-11-15 2011-09-30 Array Biopharma Inc Sposoby i związki pośrednie do otrzymywania pochodnych N4-fenylo-chinazolino-4-aminy
CN101341132A (zh) * 2005-12-21 2009-01-07 阿斯利康(瑞典)有限公司 作为mek抑制剂用于治疗癌症的6-(4-溴-2-氯-苯基氨基)-7-氟-n-(2-羟基乙氧基)-3-甲基-3h-苯并咪唑-5-甲酰胺的甲苯磺酸盐
RU2418790C3 (ru) * 2005-12-21 2022-03-14 Астразенека Аб Новая гидросульфатная соль
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
WO2008006025A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
PL2049500T3 (pl) * 2006-07-06 2012-02-29 Array Biopharma Inc Cyklopenta[d]pirymidyny jako inhibitory kinaz białkowych AKT
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008006039A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
ATE511509T1 (de) 2006-11-30 2011-06-15 Genentech Inc Azaindolylverbindungen und anwendungsverfahren
JP5311673B2 (ja) * 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
EP2404907B1 (en) * 2007-07-05 2015-01-14 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
BRPI0813999A2 (pt) 2007-07-05 2019-10-01 Array Biopharma Inc ciclopentanos de pirimidil como inibidores de akt proteína cinase
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
JP2010536723A (ja) * 2007-08-16 2010-12-02 エフ．ホフマン−ラ ロシュ アーゲー 置換ヒダントイン
WO2009064675A1 (en) 2007-11-12 2009-05-22 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
US20100004247A1 (en) * 2007-12-12 2010-01-07 Astrazeneca Ab Combination comprising a mek inhibitor and an aurora kinase inhibitor 188
WO2009080523A1 (en) 2007-12-20 2009-07-02 F. Hoffmann-La Roche Ag Substituted hydantoins as mek kinase inhibitors
AU2009204019B2 (en) * 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
KR101624753B1 (ko) * 2008-01-09 2016-05-26 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 저해물질로서의 수산화된 피리미딜 시클로펜탄
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
KR20110028651A (ko) * 2008-07-11 2011-03-21 노파르티스 아게 (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물
WO2010051933A2 (en) 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido phenoxybenzamides
PE20121816A1 (es) * 2009-10-12 2013-01-02 Hoffmann La Roche Combinaciones de un inhibidor de pi3k y un inhibidor de mek
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
CA2777071A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
CA2777430A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
US20150141380A1 (en) 2010-08-05 2015-05-21 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
PE20140192A1 (es) 2010-10-06 2014-02-24 Glaxosmithkline Llc Derivados de bencimidazol como inhibidores de cinasa pi3
US9045429B2 (en) 2010-10-29 2015-06-02 Bayer Intellectual Property Gmbh Substituted phenoxypyridines
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
HUE024504T2 (en) 2010-12-23 2016-01-28 Sanofi Sa Pyrimidine derivatives, a process for their preparation and their use in medicine
BR112013025397A2 (pt) 2011-04-01 2019-09-24 Deepak Sampath combinação de um composto, composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, uso, kit, produto, método para tratamento de um distúrbio hiperproliferativo e método para tratamento de uma doença ou afecção modulada por quinase akt em um mamífero
CA2831922C (en) 2011-04-01 2019-12-31 Genentech, Inc. Combinations of akt inhibitor compounds and vemurafenib, and methods of use
ES2597052T3 (es) 2011-05-25 2017-01-13 Université Paris Descartes Inhibidores de ERK para su uso en el tratamiento de atrofia muscular espinal
WO2013066483A1 (en) 2011-08-31 2013-05-10 Novartis Ag Synergistic combinations of pi3k- and mek-inhibitors
CN103204827B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
EP2834237B1 (en) 2012-03-14 2018-06-06 Lupin Limited Heterocyclyl compounds as mek inhibitors
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
HRP20180670T1 (hr) 2012-10-12 2018-07-13 Exelixis Inc. Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
AR099630A1 (es) 2012-10-19 2016-08-10 Novartis Ag Preparación de un inhibidor de mek y formulación que lo comprende
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
PT2976106T (pt) 2013-03-21 2021-05-26 Array Biopharma Inc Terapia de combinação que compreende um inibidor de b-raf e um segundo inibidor
WO2015038704A1 (en) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions for preparing cardiomyocytes
WO2016009306A1 (en) 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
WO2016035008A1 (en) 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
MX387795B (es) * 2016-06-03 2025-03-19 Array Biopharma Inc Combinaciones farmaceuticas.
CN109438362B (zh) 2017-11-14 2020-07-21 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑化合物及包含该化合物的组合物
JP6974618B2 (ja) * 2017-12-07 2021-12-01 ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド Ｆｇｆｒ及びｖｅｇｆｒ阻害剤としての化合物の塩形態、結晶形およびその製造方法
ES3007082T3 (en) 2018-09-18 2025-03-19 Hoffmann La Roche Quinazoline derivatives as antitumor agents
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
US11447482B1 (en) 2019-02-14 2022-09-20 KUDA Therapeutics, Inc. Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法
WO2022251193A1 (en) 2021-05-27 2022-12-01 Mirati Therapeutics, Inc. Combination therapies
CN115490640B (zh) * 2021-06-17 2024-11-26 深圳市塔吉瑞生物医药有限公司 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
WO2023283425A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
JP2024539212A (ja) 2021-10-20 2024-10-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト キナゾリン誘導体の結晶形態、調製、組成物およびその使用
CN116135839A (zh) * 2021-11-18 2023-05-19 江苏润安制药有限公司 一种阿齐沙坦关键中间体的制备方法
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750545A (en) * 1993-07-23 1998-05-12 The Green Cross Corporation Triazole derivative and pharmaceutical use thereof
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
JP2002509536A (ja) 1997-07-01 2002-03-26 ワーナー−ランバート・カンパニー ２−（４−ブロモ又は４−ヨードフェニルアミノ）安息香酸誘導体及びｍｅｋ阻害物質としてのそれらの使用
JP2002511092A (ja) 1997-07-01 2002-04-09 ワーナー−ランバート・コンパニー ４−ブロモまたは４−ヨードフェニルアミノベンズヒドロキサム酸誘導体およびそのｍｅｋ阻害剤としての使用
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
CA2350234A1 (en) 1999-01-07 2000-07-13 Alexander James Bridges Treatment of asthma with mek inhibitors
EP1140067A1 (en) 1999-01-07 2001-10-10 Warner-Lambert Company Antiviral method using mek inhibitors
BR9916857A (pt) 1999-01-13 2001-12-04 Warner Lambert Co 4 heteroaril diarilaminas
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
AP2001002225A0 (en) * 1999-01-13 2001-09-30 Warner Lambert Co 1-heterocycle substituted diarylamines.
ATE311363T1 (de) 1999-01-13 2005-12-15 Warner Lambert Co Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
EP1144371B1 (en) 1999-01-13 2005-11-09 Warner-Lambert Company Llc Benzenesulphonamide derivatives and their use as mek inhibitors
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
CN1358094A (zh) 1999-07-16 2002-07-10 沃尼尔·朗伯公司 用mek抑制剂治疗慢性疼痛的方法
HUP0202381A3 (en) 1999-07-16 2004-12-28 Warner Lambert Co Method for treating chronic pain using mek inhibitors
US7030119B1 (en) * 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
AU5786000A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
JP2003504401A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法
US7001905B2 (en) * 2000-03-15 2006-02-21 Warner-Lambert Company Substituted diarylamines as MEK inhibitors
BR0109188A (pt) 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
IL153817A0 (en) 2000-07-19 2003-07-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
MXPA03001654A (es) 2000-08-25 2004-09-10 Warner Lambert Co Proceso para la elaboracion del acido n-aril-antranilico y sus derivados.
AU2002210714A1 (en) * 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
CA2478534A1 (en) * 2002-03-13 2003-09-25 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
CA2478374C (en) * 2002-03-13 2009-01-06 Eli M. Wallace N3 alkylated benzimidazole derivatives as mek inhibitors
WO2005009975A2 (en) * 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors

Also Published As

Publication number Publication date
WO2005023251A1 (en) 2005-03-17
ES2628959T3 (es) 2017-08-04
AU2004270166A1 (en) 2005-03-17
RU2006109600A (ru) 2007-10-10
EP1663210A1 (en) 2006-06-07
IL173935A (en) 2015-08-31
CN1874768A (zh) 2006-12-06
CA2537098A1 (en) 2005-03-17
KR20060121853A (ko) 2006-11-29
US20070299063A1 (en) 2007-12-27
US7235537B2 (en) 2007-06-26
IL173935A0 (en) 2006-07-05
BRPI0413152A (pt) 2006-10-03
JP2007504139A (ja) 2007-03-01
US20040116710A1 (en) 2004-06-17
US7842816B2 (en) 2010-11-30
IS8384A (is) 2006-03-29
NO20061432L (no) 2006-08-25
EP1663210B1 (en) 2017-04-19
EP1663210A4 (en) 2009-04-22
JP5026076B2 (ja) 2012-09-12
TW200524879A (en) 2005-08-01
ZA200602588B (en) 2008-07-30
MXPA06002268A (es) 2006-05-31

Similar Documents

Publication Publication Date Title
AR045738A1 (es) Derivados de bencimidazol n3 alquilados como inhibidores de mek
AR038971A1 (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR038881A1 (es) Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos
AR051403A1 (es) Derivados de purina, purinona y deazapurina como inhibidores de la actividad de la protein quinasa; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la protein quinasa a y b.
AR076460A1 (es) Antagonistas del receptor cxcr3
AR038972A1 (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
AR039673A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metodos para su aplicacion
AR038883A1 (es) Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un metodo para prepararlos
CL2020001343A1 (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
AR044134A1 (es) Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
AR085004A1 (es) Inhibidores selectivos de glicosidasas y usos de los mismos
AR072227A1 (es) Derivados de triazinona sustituidos
BRPI0619823A8 (pt) compostos que são inibidores de erk
CL2019002919A1 (es) Compuestos inhibidores vmat2 y composiciones relacionadas.
AR046272A1 (es) Inhibidores de dipeptidil peptidasa iv
BR112015015812A2 (pt) derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor
AR043199A1 (es) Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes
AR046081A1 (es) Inhibidores heterociclicos de mek y uso de los mismos
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
UY28144A1 (es) Agentes terapéuticos
AR069510A1 (es) Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FA Abandonment or withdrawal
FB Suspension of granting procedure